Aigen Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Aigen Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$461K	Sell	881 -1,771	-67%	-$846K	0.12%	232
2025 Q4	$1.54M	Buy	2,652 +2,067	+353%	+$1.06M	0.36%	68
2025 Q3	$268K	Buy	+585	New	+$218K	0.04%	571
2025 Q1	–	Sell	-1,771	Closed	-$546K	–	913
2024 Q4	$546K	Buy	+1,771	New	+$498K	0.1%	308
2023 Q3	–	Sell	-2,270	Closed	-$524K	–	977
2023 Q2	$524K	Sell	2,270 -862	-28%	-$233K	0.08%	340
2023 Q1	$759K	Buy	+3,132	New	+$853K	0.1%	231
2020 Q4	–	Sell	-1,759	Closed	-$209K	–	931
2020 Q3	$209K	Buy	+1,759	New	+$191K	0.03%	634

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aigen Investment Management's MDGL Position: Q1 2026 in Review

Aigen Investment Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 67% in Q1 2026, selling an estimated $846K and leaving 881 shares worth $461K. The position accounts for 0.12% of the portfolio, ranked #232.

Aigen Investment Management first reported a position in MDGL in Q3 2020 and has held it in 7 quarters since. The position peaked at $1.54M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Aigen Investment Management held 881 shares of Madrigal Pharmaceuticals worth $461K as of Q1 2026.
Aigen Investment Management sold 1,771 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $846K.
Madrigal Pharmaceuticals made up 0.12% of Aigen Investment Management's portfolio in Q1 2026, its #232 holding.
Aigen Investment Management first reported a position in Madrigal Pharmaceuticals in Q3 2020 and has held it in 7 quarters since.
Aigen Investment Management's Madrigal Pharmaceuticals position peaked at $1.54M in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.